WACO, Texas, Oct. 22, 2014 /PRNewswire/ -- CANDA NK-2, LLC, a subsidiary of CANDA Pharma, LLC, announced today that the company has moved to dismiss a patent infringement lawsuit, based on lack of personal jurisdictions over the defendants. The claim was originally filed on Oct. 8, 2014 by Eli Lilly and Company (NYSE: LLY) in the United States District Court for the Southern District of Indiana. The motion to dismiss was filed in partnership with Nang Kuang Pharmaceutical Co., LTD., by Farney Daniels, PC, counsel for the defendants.
The lawsuit alleges that Nang Kuang infringed U.S. Patent Nos. 5,344,932 and 7,772,209 by submitting an Abbreviated New Drug Application to the U.S. Food & Drug Administration (FDA) requesting approval of a generic pemetrexed disodium, 100 mg base/vial and 500 mg base/vial for intravenous infusion. The pharmaceuticals are chemotherapy agents used for the treatment of various types of cancer.
The case is Eli Lilly and Company v. Nang Kuang Pharmaceutical and CANDA NK-2, No. 1:14-cv-1647.
About CANDA Pharma, LLC
CANDA Pharmaceuticals is a unique, innovative generic pharmaceutical company, focused on developing products under the FDA's Abbreviated New Drug Application (ANDA) process. CANDA collaborates with many partners for formulation, development, and commercialization of a wide variety of products and therapeutic indications that are not constrained by dosing form.
About Nang Kuang
Nang Kuang, founded in 1963, is a leading pharmaceutical company in Taiwan. Accredited with superior product quality, innovative technology, and outstanding production capacity, Nang Kuang went public in 2009. With a workforce of 485 employees and annual sales of approximately $40 million, Nang Kuang is one of the largest injectable manufacturers in Taiwan.
For more information on the litigation, contact Daniela Ritchie, CANDA Pharma, LLC, 512.582.2462 or email@example.com.